Table 4 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with short (<10 years) and long (≥10 years) duration of diabetes
From: Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
Outcome | Effect estimate | 95 % Confidence limits | p value | Effect estimate | 95 % Confidence limits | p value | ||
|---|---|---|---|---|---|---|---|---|
Lower | Upper | Lower | Upper | |||||
Short (<10 years) duration of diabetes | Long (≥10 years) duration of diabetes | |||||||
Change in HbA1c (%) | −1.28 | −1.65 | −0.91 | <0.0001 | −0.93 | −1.18 | −0.67 | <0.0001 |
Change in weight (kg) | −0.56 | −1.34 | 0.21 | 0.16 | −0.09 | −0.66 | 0.47 | 0.75 |
Change in FPG (mg/dL) | −12.7 | −26.6 | 1.2 | 0.07 | −12.6 | −24.9 | −0.4 | 0.0438 |
Change in PPG: meal test (mg/dL) | −152.6 | −182.0 | −123.2 | <0.0001 | −147.9 | −176.8 | −119.0 | <0.0001 |
Odds ratio | 95 % Confidence limits | p value | Odds ratio | 95 % Confidence limits | p value | |||
|---|---|---|---|---|---|---|---|---|
Lower | Upper | Lower | Upper | |||||
Short (<10 years) duration of diabetes | Long (≥10 years) duration of diabetes | |||||||
Symptomatic hypoglycemia | 5.2 | 1.5 | 18.7 | 0.0107 | 2.1 | 0.8 | 5.2 | 0.11 |
Severe hypoglycemia | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – |
Endpoint HbA1c <7 % | 32.1 | 4.2 | 246.6 | 0.0009 | 8.9 | 2.5 | 31.9 | 0.0008 |
Endpoint HbA1c <7 % and no weight gain | 22.5 | 2.9 | 174.3 | 0.0028 | 6.3 | 1.7 | 23.3 | 0.0057 |
Endpoint HbA1c <7 % and no symptomatic hypoglycemia | 19.8 | 2.6 | 153.5 | 0.0043 | 9.0 | 2.0 | 41.1 | 0.0046 |
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia | 11.6 | 1.4 | 93.3 | 0.0213 | 7.5 | 1.6 | 34.7 | 0.0099 |